Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00628745 · ClinicalTrials.gov registry record
Transthyretin Amyloidosis Outcome Survey (THAOS)
A clinical trial of Transthyretin Amyloidosis and Transthyretin Gene Mutations, sponsored by Pfizer.
- Completed
- Registry status
- 6,718
- Enrollment target
- 20
- Study locations
NCT00628745: Completed study of Transthyretin Amyloidosis and Transthyretin Gene Mutations, sponsored by Pfizer.
NCT00628745 is a study of Transthyretin Amyloidosis and Transthyretin Gene Mutations that has completed, run by Pfizer. The registered enrollment target is 6,718 participants, above the 419-participant average among 8 other Transthyretin Amyloidosis trials with a reported enrollment target (1503% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00628745, a study of Transthyretin Amyloidosis and Transthyretin Gene Mutations, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 6,718 participants
- Enrollment target
- 20
- Study locations
Study Summary
THAOS is a global, multi-center, longitudinal observational survey open to all patients with transthyretin amyloidosis (ATTR), including ATTR-PN (polyneuropathy), ATTR-CM (cardiomyopathy) and wild-type ATTR-CM. It is open-ended with a minimum duration of 10 years. Patients will be followed as long as they are able to participate. The principal aims of this outcome survey are to better understand and characterize the natural history of the disease by studying a large and heterogenous patient population. Survey data may be used to develop new treatment guidelines and recommendations, and to inform and educate clinicians about the management of this disease.
Primary Outcome
An AE was any untoward medical occurrence in a participant who administered a medicinal product without regard to possibility of causal relationship with the study treatment. SAE was defined as one of the following: resulted in death; was life-threatening (immediate risk of death); requires inpatient hospitalization or prolongation of hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); constituted
Conditions Studied
Interventions
- OTHER None. Observational Study.
Study Locations (20)
California
- VA Greater Los Angeles Healthcare System - Los Angeles
- University of California, Irvine - Orange
- University of California - San Francisco, UCSF Department of Neurology - San Francisco
- Office of Sponsored Research - San Francisco
- Stanford University School of Medicine - Stanford
Illinois
- Clinical Trials Unit - Chicago
- Northwestern University - Chicago
- University of Chicago Medical Center IRB - Chicago
- University of Chicago Medical Center - Chicago
- Advocate Christ Medical Centre - Oak Lawn
Florida
- UHealth Deerfield Beach - Deerfield Beach
- University of Miami Hospital & Clinics - Miami
- UHealth Plantation - Plantation
Maryland
- University of Maryland School of Medicine - Baltimore
- University of Maryland - Baltimore
Alabama
- University of Alabama at Birmingham - Birmingham
Arizona
- Mayo Clinic Arizona - Phoenix
Colorado
- UC Denver - Aurora
Connecticut
- Smilow Cancer Hospital at Yale-New Haven - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,718 participants |
| Start Date | 2008-01-04 |
| Est. Completion | 2023-06-19 |
What the finished NCT00628745 record still lists
NCT00628745 is an observational study that tracks outcomes without assigning an intervention. Its 6,718 participants enrollment target places it among the larger protocols in the corpus, above the 419-participant average among 8 other Transthyretin Amyloidosis trials with a reported enrollment target (1503% higher).
The record links to 2 conditions, with Transthyretin Amyloidosis appearing as the primary indexed condition, and to 1 intervention - of which None. Observational Study. is the first listed.
NCT00628745 names 20 study sites across 9 states, led by California, Illinois, Florida.
Frequently Asked Questions
What is clinical trial NCT00628745 about?
NCT00628745 is a clinical study titled "Transthyretin Amyloidosis Outcome Survey (THAOS)". THAOS is a global, multi-center, longitudinal observational survey open to all patients with transthyretin amyloidosis (ATTR), including ATTR-PN (polyneuropathy), ATTR-CM (cardiomyopathy) and wild-type ATTR-CM. It is open-ended with a minimum duration of 10 years. Patients will be followed as long a...
What is the current status of trial NCT00628745?
This trial is currently completed. The enrollment target is 6,718 participants. The study started on 2008-01-04. Estimated completion is 2023-06-19.
What conditions does trial NCT00628745 study?
This clinical trial studies the following conditions: Transthyretin Amyloidosis, Transthyretin Gene Mutations.
What interventions are being tested in trial NCT00628745?
The interventions under investigation include: None. Observational Study. (OTHER).
Who is sponsoring clinical trial NCT00628745?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00628745 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Transthyretin Amyloidosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00628745's enrollment target sits among peer trials
6,718 1st of 8 higher than 8 of 8 other Transthyretin Amyloidosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Transthyretin Amyloidosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis
RECRUITING · Phase 2
-
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
RECRUITING
-
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
RECRUITING · Phase 3
-
Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF
RECRUITING · NA
-
Spectrum of Peripheral and Autonomic Neuropathies in Patients With aTTRwt Amyloidosis and Response to Patisiran Therapy
ACTIVE NOT RECRUITING · Early Phase 1
-
Monitoring of Early Disease Progression in Hereditary Transthyretin Amyloidosis
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05121324 · 6,700 participants · Phase 3
Pediatric Dose Optimization for Seizures in Emergency Medical Services
- NCT03887715 · 6,800 participants · NA
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression
- NCT06272045 · 6,618 participants · NA
Early Intervention to Promote Cardiovascular Health of Mothers and Children
- NCT06234384 · 6,833 participants
Foundation for Sarcoidosis Research Advanced Cures Registry (FSR-SARC Registry)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI